CONFIRM was a 2-year , placebo-controlled study of the efficacy and safety of DMF 240 mg twice ( BID ) or 3 times daily ( TID ) in 1,417 patients with relapsing-remitting multiple sclerosis ( RRMS ) ; subcutaneous glatiramer acetate 20 mg once daily was included as an active reference comparator .